Translating Adenosine A24 Receptor Biology into Novel Therapies for Parkinson's Disease
Abstract
Recent advances in the pharmacology, neurotoxicology and epidemiology of the adenosine A2A receptor have provided evidence that A2A receptor antagonists (including caffeine) may offer therapeutic benefits in Parkinson's disease (PD) at multiple levels. Not only does A2A receptor blockade reduce the symptomatic psychomotor slowing characteristic of PD, but based on recent preclinical data on rodents and non-human primates A2a receptor blockade potentially can attenuate neurotoxin-induced dopaminergic neuron loss and the development of maladaptive (dyskinetic) responses to chronic dopaminergic therapy. The conference and post-conference publication have been organized to systematically explore the role of the A2A receptor in PD through sequential themes leading from A2AR, neurobiology to the development of clinical trials for A2A antagonists in PD. The purpose of our post-conference publication a special supplement issue of the journal Neurology is to broad disseminate the information generated by the conference to a wide audience of basic and clinical neuroscientists in academics, government and industry. Given this journal's high profile and direct distribution of 20,000 as well as PubMed indexing, the publication will markedly enhance the dissemination of information coming out of the conference.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2002
- Accession Number
- ADA419292
Entities
People
- Michael A Schwarzschild
Organizations
- Massachusetts General Hospital